Kovack Advisors’s Cyclerion Therapeutics CYCN Stock Holding History

Kovack Advisors’s Portfolio CYCN Stock Details CYCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-10,000	Closed	-$15.5K	–	1091
2026 Q1	$15.5K	Buy	+10,000	New	+$14.2K	﹤0.01%	1008

Other funds holding CYCN

KCM

Kalehua Capital Management Dallas, Texas $174M AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Rangeley Capital New Canaan, Connecticut $109M AUM 97.13% 1-Year Est. Return

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Kovack Advisors's CYCN Position: Q2 2026 in Review

Kovack Advisors sold out of Cyclerion Therapeutics (CYCN) in Q2 2026, closing a stake of 10,000 shares — an estimated $15.5K sold.

Kovack Advisors first reported a position in CYCN in Q1 2026 and held it in 1 quarter. The position peaked at $15.5K in Q1 2026. 21 funds tracked by Wall St. Rank hold CYCN as of Q2 2026.

Kovack Advisors reported no remaining Cyclerion Therapeutics position as of Q2 2026 after selling out during the quarter.
Kovack Advisors sold 10,000 Cyclerion Therapeutics shares in Q2 2026, an estimated $15.5K.
Kovack Advisors first reported a position in Cyclerion Therapeutics in Q1 2026 and held it in 1 quarter.
Kovack Advisors's Cyclerion Therapeutics position peaked at $15.5K in Q1 2026.
21 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q2 2026.

Based on Kovack Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.